Doxorubicin increased the expression of the MAP1LC3B and BECN1 genes and elevated the concentrations of Beclin-1 and LC3B in the MCF-7 and MDA-MB-231 breast cancer cells. The gene discussed is MAP1LC3B; the disease is breast carcinoma.